Allergy Therapeutics plc announced that Nick Wykeman, Chief Financial Officer has tendered his resignation, with effect from November 30, 2022, in order to pursue non-executive roles. Nick Wykeman, who has been a Director of Allergy Therapeutics for six years, remains in his role for six months and a search for his successor will now commence.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 GBX | -2.94% | +3.12% | +32.00% |
1st Jan change | Capi. | |
---|---|---|
+32.00% | 200M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.12% | 21.97B | |
-4.64% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- AGY Stock
- News Allergy Therapeutics plc
- Allergy Therapeutics plc Announces Resignation of Nick Wykeman as Chief Financial Officer, effective from November 30, 2022